MT-125, a selective inhibitor of non-muscle myosin II, targets glioblastoma's tumor proliferation and resistance mechanisms. The FDA's fast track designation aims to expedite MT-125's development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback